Study of Olverembatinib (HQP1351) in Patients With CML-CP
POLARIS-2
A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)
1 other identifier
interventional
333
16 countries
163
Brief Summary
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure criteria while receiving bosutinib in Part A may be able to receive olverembatinib in crossover follow-on study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Feb 2024
Typical duration for phase_3
163 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 5, 2024
CompletedFirst Submitted
Initial submission to the registry
May 16, 2024
CompletedFirst Posted
Study publicly available on registry
May 21, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 10, 2028
September 15, 2026
September 1, 2026
3.4 years
May 16, 2024
September 10, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
24-Week MMR Rate (Part A)
To compare the major molecular response (MMR) rate at 24 weeks for olverembatinib versus bosutinib
24 weeks
24-Week MMR Rate (Part B)
To evaluate the MMR rate by 24 weeks for olverembatinib in CML-CP patients with T315I mutation
24 weeks
Secondary Outcomes (10)
96-Week MMR Rate (Part A)
96 weeks
96-Week MMR Rate (Part B)
96 weeks
Cytogenic Response Rate (Part A)
Through 96 weeks (i.e., at 24, 48, and 96 weeks)
Cytogenic Response Rate (Part B)
Through 96 weeks (i.e., at 24, 48, and 96 weeks)
Progression Free Survival (PFS) (Part A)
5 years after the last patient received the first study dose
- +5 more secondary outcomes
Study Arms (2)
Part A, RCT, olverembatinib arm and bosutinib arm
OTHERRandomized controlled part that is designed to compare the efficacy and safety of olverembatinib (investigational arm) versus bosutinib (control arm) in patients with CML-CP, previously treated with at least two TKIs
Part B, SAT, olverembatinib arm
OTHERTo evaluate the efficacy and safety of olverembatinib in the CML-CP patients with T315I mutation previously
Interventions
olverembatinib QOD
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years old
- Diagnosis of CML-CP
- Part A: Previously treated with at least two approved TKIs; Part B: T315I mutation at screening and previously treated with at least one approved TKI, with no other effective and/or tolerable therapies available
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
- Patient has adequate organ function
You may not qualify if:
- Patients eligible for this study must not meet any of the following criteria:
- For Part A only: T315I or V299L mutation at any time prior to starting study treatment
- Active infection that requires systemic drug therapy
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of study drugs
- Previous treatment with or known / suspected hypersensitivity to olverembatinib or any of its excipients
- Previous treatment with or known / suspected hypersensitivity to bosutinib or any of its excipients
- Pregnant or nursing (lactating) women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (163)
Ascentage Investigative Site #1044
Birmingham, Alabama, 35249, United States
Ascentage Investigative Site #1112
Anchorage, Alaska, 99508, United States
Ascentage Investigative Site #1111
Goodyear, Arizona, 85338, United States
Ascentage Investigative Site #1062
Duarte, California, 91010, United States
Ascentage Investigative Site #1099
Irvine, California, 92618, United States
Ascentage Investigative Site #1075
La Jolla, California, 92037, United States
Ascentage Investigative Site #1100
Long Beach, California, 90813, United States
Ascentage Investigative Site #1059
Los Angeles, California, 90024, United States
Ascentage Investigative Site #1121
Sacramento, California, 95817, United States
Ascentage Investigative Site #1109
Upland, California, 91786, United States
Ascentage Investigative Site #1045
Augusta, Georgia, 30912, United States
Ascentage Investigative Site #1110
Newnan, Georgia, 30265, United States
Ascentage Investigative Site #1055
Chicago, Illinois, 60637, United States
Ascentage Investigative Site #1095
Decatur, Illinois, 62526, United States
Ascentage Investigative Site #1069
Indianapolis, Indiana, 46237, United States
Ascentage Investigative Site #1065
Wichita, Kansas, 67214, United States
Ascentage Investigative Site #1084
Lexington, Kentucky, 40536, United States
Ascentage Investigative Site #1058
Louisville, Kentucky, 40202, United States
Ascentage Investigative Site #1801
Baltimore, Maryland, 21201, United States
Ascentage Investigative Site #1056
Detroit, Michigan, 48201, United States
Ascentage Investigative Site #1023
Detroit, Michigan, 49254, United States
Ascentage Investigative Site #1088
St Louis, Missouri, 63108, United States
Ascentage Investigative Site #1097
Lincoln, Nebraska, 68506, United States
Ascentage Investigative Site #1066
Las Vegas, Nevada, 89169, United States
Ascentage Investigative Site #1113
Reno, Nevada, 89511, United States
Ascentage Investigative Site #1064
Hackensack, New Jersey, 07601, United States
Ascentage Investigative Site #1054
Morristown, New Jersey, 07960, United States
Ascentage Investigative Site #1098
New Brunswick, New Jersey, 08901, United States
Ascentage Investigative Site #1072
Albuquerque, New Mexico, 87102, United States
Ascentage Investigative Site #1068
Rochester, New York, 14642, United States
Ascentage Investigative Site #1053
Shirley, New York, 11967, United States
Ascentage Investigative Site #1160
Stony Brook, New York, 11794, United States
Ascentage Investigative Site #1019
Greenville, North Carolina, 27858, United States
Ascentage Investigative Site #1043
Morrisville, North Carolina, 27560, United States
Ascentage Investigative Site #1173
Cleveland, Ohio, 44111, United States
Ascentage Investigative Site #1096
Cleveland, Ohio, 44195, United States
Ascentage Investigative Site #1174
Mayfield Heights, Ohio, 44124, United States
Ascentage Investigative Site #1139
Portland, Oregon, 97239, United States
Ascentage Investigative Site #1057
Philadelphia, Pennsylvania, 19104, United States
Ascentage Investigative Site #1022
Pittsburgh, Pennsylvania, 15232, United States
Ascentage Investigative Site #1063
Chattanooga, Tennessee, 37404, United States
Ascentage Investigative Site #1089
Nashville, Tennessee, 37203, United States
Ascentage Investigative Site #1051
Amarillo, Texas, 79124, United States
Ascentage Investigative Site #1036
Austin, Texas, 78705, United States
Ascentage Investigative Site #1501
Houston, Texas, 77030, United States
Ascentage Investigative Site #1050
Virginia Beach, Virginia, 23456, United States
Ascentage Investigative Site #1136
Edmonds, Washington, 98026, United States
Ascentage Investigative Site #1135
Issaquah, Washington, 98029, United States
Ascentage Investigative Site #1806
Seattle, Washington, 98104, United States
Ascentage Investigative Site #1510
Seattle, Washington, 98109, United States
Ascentage Investigative Site #2107
Campbelltown, New South Wales, 2560, Australia
Ascentage Investigative Site #2105
Liverpool, New South Wales, 2170, Australia
Ascentage Investigative Site #2115
Adelaide, South Australia, 5000, Australia
Ascentage Investigative Site #2106
Perth, Western Australia, 6000, Australia
Ascentage Investigative Site #5211
Anderlecht, 1070, Belgium
Ascentage Investigative Site #5212
Gilly, 6060, Belgium
Ascentage Investigative Site #5208
Kortrijk, 8500, Belgium
Ascentage Investigative Site #5209
Roeselare, 8800, Belgium
Ascentage Investigative Site #5210
Yvoir, 5530, Belgium
Ascentage Investigative Site #8004
Toronto, M5G 2M9, Canada
Ascentage Investigative Site #5037
Amiens, 80054, France
Ascentage Investigative Site #5015
Bobigny, 93000, France
Ascentage Investigative Site #5017
Nice, 06202, France
Ascentage Investigative Site #5016
Rouen, 76038, France
Ascentage Investigative Site #5023
Toulouse, 31059, France
Ascentage Investigative Site #5708
Berlin, 13353, Germany
Ascentage Investigative Site #5709
Dresden, 01307, Germany
Ascentage Investigative Site #9118
Bangalore, 560027, India
Ascentage Investigative Site #9120
Haryāna, 122002, India
Ascentage Investigative Site #9102
Haryāna, 124105, India
Ascentage Investigative Site #9110
Hyderabad, 500033, India
Ascentage Investigative Site #9116
Kolkata, 700014, India
Ascentage Investigative Site #9115
Kolkata, 700054, India
Ascentage Investigative Site #9101
New Delhi, 110029, India
Ascentage Investigative Site #9103
New Delhi, 110076, India
Ascentage Investigative Site #9119
Pune, 411001, India
Ascentage Investigative Site #9113
Thiruvananthapuram, 695011, India
Ascentage Investigative Site #5535
Bologna, 40138, Italy
Ascentage Investigative Site #5534
Candiolo, 10060, Italy
Ascentage Investigative Site #5527
Catania, 95123, Italy
Ascentage Investigative Site #5523
Lecce, 73100, Italy
Ascentage Investigative Site #5529
Meldola, 47014, Italy
Ascentage Investigative Site #5537
Messina, 98124, Italy
Ascentage Investigative Site #5553
Milan, 20122, Italy
Ascentage Investigative Site #5530
Naples, 80131, Italy
Ascentage Investigative Site #5524
Novara, 28100, Italy
Ascentage Investigative Site #5525
Padova, 35128, Italy
Ascentage Investigative Site #5526
Pisa, 56126, Italy
Ascentage Investigative Site #5528
Roma, 00144, Italy
Ascentage Investigative Site #5522
Roma, 00161, Italy
Ascentage Investigative Site #5510
Roma, 00168, Italy
Ascentage Investigative Site #5552
Torino, 10126, Italy
Ascentage Investigative Site #5521
Torino, 10128, Italy
Ascentage Investigative Site #5536
Varese, 21100, Italy
Ascentage Investigative Site #8101
Ehime, 790-8524, Japan
Ascentage Investigative Site #8102
Kyoto, 602-8566, Japan
Ascentage Investigative Site #8112
Okayama, 701-1192, Japan
Ascentage Investigative Site #8105
Osaka, 565-0871, Japan
Ascentage Investigative Site #8106
Sapporo, 003-0006, Japan
Ascentage Investigative Site #8107
Sapporo, 060-8648, Japan
Ascentage Investigative Site #8109
Tochigi, 321-0207, Japan
Ascentage Investigative Site #8114
Tokyo, 113-8677, Japan
Ascentage Investigative Site #8117
Tokyo, 130-8575, Japan
Ascentage Investigative Site #8110
Tokyo, 141-8625, Japan
Ascentage Investigative Site #8104
Yamagata, 990-9585, Japan
Ascentage Investigative Site #8103
Yamanashi, 409-3898, Japan
Ascentage Investigative Site #4213
Gdansk, 80214, Poland
Ascentage Investigative Site #4212
Gdansk, 80219, Poland
Ascentage Investigative Site #4207
Katowice, 40519, Poland
Ascentage Investigative Site #4209
Krakow, 30688, Poland
Ascentage Investigative Site #4211
Lodz, 93513, Poland
Ascentage Investigative Site #4214
Torun, 87100, Poland
Ascentage Investigative Site #4206
Warsaw, 00791, Poland
Ascentage Investigative Site #4210
Wałbrzych, 58309, Poland
Ascentage Investigative Site #3227
Moscow, 125167, Russia
Ascentage Investigative Site #3228
Saint Petersburg, 191024, Russia
Ascentage Investigative Site #3213
Saint Petersburg, 194291, Russia
Ascentage Investigative Site #3212
Saint Petersburg, 197341, Russia
Ascentage Investigative Site #6602
Singapore, 117599, Singapore
Ascentage Investigative Site #6601
Singapore, 168583, Singapore
Ascentage Investigative Site #8206
Busan, 49201, South Korea
Ascentage Investigative Site #8207
Busan, 49241, South Korea
Ascentage Investigative Site #8204
Gyeonggi-do, 13620, South Korea
Ascentage Investigative Site #8201
Seoul, 03080, South Korea
Ascentage Investigative Site #8202
Seoul, 05505, South Korea
Ascentage Investigative Site #8205
Seoul, 06351, South Korea
Ascentage Investigative Site #8203
Seoul, 06591, South Korea
Ascentage Investigative Ste #8208
Uijeongbu-si, 11749, South Korea
Ascentage Investigative Site #6015
Badalona, 08916, Spain
Ascentage Investigative Site #6020
Barcelona, 08035, Spain
Ascentage Investigative Site #6047
Elche, 03293, Spain
Ascentage Investigative Site #6014
L'Hospitalet de Llobregat, 08906, Spain
Ascentage Investigative Site #6035
Madrid, 28006, Spain
Ascentage Investigative Site #6013
Madrid, 28007, Spain
Ascentage Investigative Site #6033
Madrid, 28031, Spain
Ascentage Investigative Site #6011
Madrid, 28041, Spain
Ascentage Investigative Site #6032
Madrid, 28046, Spain
Ascentage Investigative Site #6037
Majadahonda, 28222, Spain
Ascentage Investigative Site #6012
Málaga, 29010, Spain
Ascentage Investigative Site #6039
Málaga, 29010, Spain
Ascentage Investigative Site #6051
Murcia, 30120, Spain
Ascentage Investigative Site #6036
Ourense, 32005, Spain
Ascentage Investigative Site #6038
Valencia, 46017, Spain
Ascentage Investigative Site #6041
Zaragoza, 50009, Spain
Ascentage Investigative Site #9216
Adapazarı, 54100, Turkey (Türkiye)
Ascentage Investigative Site #9218
Ankara, 06050, Turkey (Türkiye)
Ascentage Investigative Site #9204
Ankara, 06170, Turkey (Türkiye)
Ascentage Investigative Site #9215
Battalgazi, 44210, Turkey (Türkiye)
Ascentage Investigative Site #9217
Çankaya, 06800, Turkey (Türkiye)
Ascentage Investigative Site #9219
Istanbul, 34452, Turkey (Türkiye)
Ascentage Investigative Site #9205
Kepez, 07025, Turkey (Türkiye)
Ascentage Investigative Site #9208
Mezitli, 33200, Turkey (Türkiye)
Ascentage Investigative Site #9213
Ortahisar, 61080, Turkey (Türkiye)
Ascentage Investigative Site #9214
Samsun, 55270, Turkey (Türkiye)
Ascentage Investigative Site #9212
Yenimahalle, 06200, Turkey (Türkiye)
Ascentage Investigative Site #7017
Aberdeen, AB25 2ZN, United Kingdom
Ascentage Investigative Site #7036
Birmingham, B15 2GW, United Kingdom
Ascentage Investigative Site #7021
Boston, PE21 9QS, United Kingdom
Ascentage Investigative Site #7037
Bradford, BD9 6RJ, United Kingdom
Ascentage Investigative Site #7035
Liverpool, L7 8YA, United Kingdom
Ascentage Investigative Site #7016
London, SE5 9RS, United Kingdom
Ascentage Investigative Site #7015
London, W12 0HS, United Kingdom
Ascentage Investigative Site #7018
Newport, NP20 2UB, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Elias Jabbour, M.D.
M.D. Anderson Cancer Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
- Expanded Access
- Yes
Study Record Dates
First Submitted
May 16, 2024
First Posted
May 21, 2024
Study Start
February 5, 2024
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
July 10, 2028
Last Updated
September 15, 2026
Record last verified: 2026-09